Sickle Cell Disease news and research updates
Research readouts, treatment and access decisions, and community updates for people living with sickle cell disease and the people who care for them — each one dated, with a link to the original source where there is one.
444 articlesFree, no login required
Looking for earlier coverage? Browse the news archive.
$3M Breakthrough Prize honors duo whose work changed SCD treatment
One of the $3 million 2026 Breakthrough Prizes — in Life Sciences — has been awarded to two researchers whose discoveries reshaped the treatment of sickle cell disease (SCD). The…
Nigeria emerges as global epicentre of sickle cell cases in children — Study
Nigeria now bears the world’s highest burden of sickle cell disease among children, with more than 1.5 million cases recorded in those under 15, according to a new international…
Agios Stock Sinks 23% as NVO's PKR Activator Meets Goal in SCD Study
Shares of Agios Pharmaceuticals AGIO declined sharply by 23% on Monday after Novo Nordisk NVO announced positive top-line data for its investigational drug, etavopivat, for the…
Novo Nordisk preps filings for sickle cell drug etavopivat
Novo Nordisk is planning to move ahead with regulatory filings for etavopivat, potentially a first-in-class therapy for sickle cell disease, based on positive results in a phase 3…
Etavopivat Phase 3 results support potential approval in sickle cell disease
A global, late-stage clinical trial testing etavopivat in people with sickle cell disease (SCD) has hit its main goals, showing that the experimental oral therapy improved…
Novo readies SCD drug from $1.1B Forma buyout for approval push after phase 3 win
Novo Nordisk is gearing up to submit its rare blood disorder drug to the FDA after the former Forma Therapeutics asset reduced a painful complication of sickle cell disease (SCD)…
Clinical Outcomes of Lentiviral Vector Gene Therapy for Sickle Cell Disease
Sickle cell disease (SCD) is a monogenic disorder where autologous gene therapy may offer a safer curative alternative to allogeneic transplantation. We report outcomes from a…
Novo’s late-stage sickle cell win piles pressure on competitors
Novo Nordisk’s etavopivat elicited a 27% drop in vaso-occlusive crises and 48.7% hemoglobin response after 24 weeks, creating “separation amongst PK class candidates,” Truist…
Sickle cell vaso-occlusive episodes correlate with the magnetic heterogeneity of red blood cells
Sickle cell disease (SCD) is a complex condition that results in low oxygen affinity and oxidative damage within red blood cells (RBCs), which contributes to serious complications…
Serum Vitamin A levels in children with sickle cell anemia: relationship with pulmonary function indices
Abstract Background Vitamin A is involved in the proliferation and maintenance of the epithelial cells of the respiratory tract. Since maintenance of the integrity of the…
Novo Nordisk to seek oral sickle cell therapy approval after Phase III victory
APhase III trial of Novo Nordisk’s once-daily tablet has met both co-primary endpoints, reducing vaso-occlusive crises (VOC) and increasing haemoglobin (Hb) response in patients…
High-Altitude Hypoxemia in Adults With Sickle Cell Disease (SCD
Sickle cell disease (SCD) is characterized by abnormal polymerization of deoxygenated hemoglobin S. This polymerization leads to the distinctive sickling of red blood cells (RBC)…